SEBI Reg. Investment Advisor

Download App

Help Center Pricing

Recent:

Log In Sign Up Schedule Free 15‑min Call

Top Pharma Companies in India by Market Cap

BSE Sensex 77844.52
114 (-0.15%)

Filter

Top Pharma Companies in India as on May-2026 | 5 Star Rated Stocks Undervalued Stocks Fair Valued Stocks Uptrend Stocks

Filter

	Company Name	DeciZen	Market cap (Rs. Cr.)	CMP (Change %)	Latest P/E	Latest P/BV	5Y Sales Gr.(%)	5Y Profit Gr.(%)
121	Kovai Medical Center & Hospital Ltd.	Q V+ PT	6,253 Small Cap	5,757.45 (0.76%)	26.52	4.98	14.01	17.17	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
122	Divis Laboratories Ltd.	Q V+ PT	1,78,026 Large Cap	6,700.75 (-0.08%)	71.81	11.13	11.65	10.50	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
123	Apollo Hospitals Enterprise Ltd.	Q V+ PT	1,11,527 Large Cap	7,837.85 (1.05%)	77.25	11.5	-3.49	29.94	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
124	Astrazeneca Pharma India Ltd.	Q V+ PT	20,924 Small Cap	8,535.30 (1.98%)	104.15	25.16	15.59	20.47	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
125	Neuland Laboratories Ltd.	Q V+ PT	21,775 Small Cap	17,300.45 (1.94%)	122.11	13.18	14.13	64.99	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
126	Abbott India Ltd.	Q V PT	55,876 Mid Cap	26,692.15 (1.51%)	36.66	12.74	9.38	18.78	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
Prev 1 2 3 4 5 Next

Screens:

AlphaCases Top Rated Stocks Best Nifty Stocks Best Nifty Next Stocks Best Nifty 500 Stocks Best SmallCap Stocks Top BFSI Stocks

Pharma - Today's Top Gainers

Company Name	CMP	Price Change(%)
Piramal Pharma	183.85	11.36%
Indoco Remedies	251.25	10.22%
Nectar Lifesciences	13.59	9.95%
Sun Pharma Adv. Res	166.95	6.30%
Guj. Kidney & Super	130.90	6.03%

Pharma - Today's Top Losers

Company Name	CMP	Price Change(%)
Wockhardt	1,636.75	-4.85%
Rubicon Research	951.90	-4.72%
Wanbury	252	-2.25%
Concord Biotech	1,197.15	-2.12%
Aarti Pharmalabs	776.60	-1.51%

News about Top Pharma Companies in India

29

Apr, 2026

Neuland Laboratories submits earnings call intimation

Neuland Laboratories has informed that the company will announce its results for the fourth quarter and full year ended March 31, 2026 on May 12, 2026. The results will also be made available on the website of the Company, www.neulandlabs.com. Following the announcement, the management of the Company will host an Earnings Call on May 12, 2026 at 17:30 hrs.

The above information is a part of company’s filings submitted to BSE.

22

Apr, 2026

Abbott India informs about change in management

Abbott India has informed about following outcome of the Board Meeting held today i.e., April 22, 2026. Anisha Motwani (DIN: 06943493), Independent Director, will be completing her second term as an Independent Director of the Company on April 24, 2026. Accordingly, she ceases to be the Director of the Company with effect from the close of business hours on April 24, 2026. Details pursuant to SEBI Master Circular No. HO/49/14/14(7)2025-CFDPOD2/I/3762/2026 dated January 30, 2026 (SEBI Circular), is enclosed as Annexure; Appointment of Neeraj Jain (DIN: 00348591) as an Additional Director designated as an Independent Director, with effect from April 25, 2026; etc.

The above information is a part of company’s filings submitted to BSE.

18

Apr, 2026

Apollo Hospitals Enterprise informs about scheme of arrangement

Apollo Hospitals Enterprise has informed that it enclosed update on Order of the Hon'ble National Company Law Tribunal, Division Bench - II, Chennai (Tribunal) in relation to the proposed composite scheme of arrangement.

The above information is a part of company’s filings submitted to BSE.

14

Apr, 2026

Neuland Laboratories informs about press release

Neuland Laboratories has informed that it enclosed copies of newspaper advertisement informing about the launch of Second 100 Days Campaign - ‘Saksham Niveshak’ starting from April 1, 2026 to July 9, 2026, in accordance with IEPFA, letter dated March 27, 2026, as published in Financial Express and Nava Telangana on April 14, 2026.

The above information is a part of company’s filings submitted to BSE.

14

Apr, 2026

Neuland Laboratories informs about newspaper advertisement

Pursuant to Regulation 47 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulation, 2015, Neuland Laboratories has informed that it enclosed copies of newspaper advertisement informing about the launch of Second 100 Days Campaign – ‘Saksham Niveshak’ starting from April 1, 2026 to July 9, 2026, in accordance with IEPFA, letter dated March 27, 2026, as published in Financial Express and Nava Telangana on April 14, 2026.

The above information is a part of company’s filings submitted to BSE.

13

Apr, 2026

AstraZeneca Pharma surges on getting nod to import, market Acalabrutinib tablets 100 mg

The company has received permission from the Central Drugs Standard Control Organisation

Publicly traded pharmaceuticals

Top 10 Publicly Listed pharmaceutical stocks in India by Market Capitalization as of 2026.

Rank	Company	Market Capitalization 2026 (INR crores)
1	Nectar Lifesciences Ltd.	240 Crore
2	Syncom Formulations (India) Ltd.	1,351 Crore
3	Sigachi Industries Ltd.	765 Crore
4	Fischer Medical Ventures Ltd.	2,506 Crore
5	Morepen Laboratories Ltd.	2,387 Crore
6	Anuh Pharma Ltd.	829 Crore
7	KMC Speciality Hospitals (India) Ltd.	1,412 Crore
8	IOL Chemicals And Pharmaceuticals Ltd.	2,816 Crore
9	Themis Medicare Ltd.	916 Crore
10	Gujarat Kidney And Super Speciality Ltd.	973 Crore

Do you know? Asking 3 Right Questions minimizes the RISK of Stock Investing To Know

Right Stock | Right Price | Right Allocation

Find best stocks to buy now Find best pharma stocks to buy now

Top 15 Pharma Stocks by Revenue Growth

Top Pharma Companies Source: NSE Indices

You can use different criterias to arrive at the list of best stocks in the Nifty Pharma company index. You can use return ratios like ROCE or ROE, that will help you choose companies with profitable growth.

Based on ROE, the best stocks in the Nifty Pharma companies index are:

Company Name	Is it a Right Stock ?	CMP	Market Cap(Cr.)	P/E	P/BV	EV/EBITDA	ROE
Abbott India Ltd. (M)	Very Good	26,692	55,876	36.66	12.74	25.65	35.71
Torrent Pharmaceuticals Ltd. (L)	Very Good	4,359	1,47,478	64.91	16.23	36.68	26.68
Ajanta Pharma Ltd. (S)	Very Good	3,080	38,646	36.60	8.54	24.73	24.45
Lupin Ltd. (M)	Somewhat Good	2,460	1,11,668	24.04	5.37	14.31	20.83
Zydus Lifesciences Ltd. (M)	Very Good	940	94,495	19.13	3.60	11.92	20.74

Based on the past year's gain, the best performing stocks are:

Company Name	Is it a Right Stock ?	CMP	Market Cap(Cr.)	Yearly gain (%)
Laurus Labs Ltd. (M)	Very Good	1,206	63,517	92.14
Glenmark Pharmaceuticals Ltd. (M)	Very Good	2,371	66,987	68.93
JB Chemicals & Pharmaceuticals Ltd. (S)	Very Good	2,141	34,370	42.38
Wockhardt Ltd. (S)	Not Good	1,637	27,953	39.71
Torrent Pharmaceuticals Ltd. (L)	Very Good	4,359	1,47,478	33.30
				View More

Stocks with the highest revenue growth in the past 5 years is:

Company Name	Is it a Right Stock ?	CMP	Market Cap(Cr.)	P/E	P/BV	EV/EBITDA	5Y Sales Growth (%)
JB Chemicals & Pharmaceuticals Ltd. (S)	Very Good	2,141	34,370	47.25	8.81	29.84	17.81
Mankind Pharma Ltd. (M)	Very Good	2,375	97,506	57.24	6.11	34.36	14.65
Laurus Labs Ltd. (M)	Very Good	1,206	63,517	71.46	11.98	35.90	14.42
Dr. Reddys Laboratories Ltd. (M)	Very Good	1,307	1,09,382	19.64	2.94	11.80	13.26
Ajanta Pharma Ltd. (S)	Very Good	3,080	38,646	36.60	8.54	24.73	12.43

Stocks with high profit growth often witness their stock prices gaining, irrespective of the market movements.

Stocks with the highest profit growth in the past 5 years is:

Company Name	Is it a Right Stock ?	CMP	Market Cap(Cr.)	P/E	P/BV	EV/EBITDA	5Y Profit Growth (%)
Zydus Lifesciences Ltd. (M)	Very Good	940	94,495	19.13	3.60	11.92	30.57
Cipla Ltd. (L)	Very Good	1,363	1,10,283	24.26	3.28	14.63	30.14
Sun Pharmaceutical Industries Ltd. (L)	Very Good	1,834	4,43,973	40.67	5.47	22.24	23.50
Dr. Reddys Laboratories Ltd. (M)	Very Good	1,307	1,09,382	19.64	2.94	11.80	22.29
JB Chemicals & Pharmaceuticals Ltd. (S)	Very Good	2,141	34,370	47.25	8.81	29.84	19.45

You have 2 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login | Register Now

2026 ©The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me® is a registered trademark of The Alchemists Ark Pvt. Ltd.

About MoneyWorks4Me

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Fiduciary-first advisory model.
As SEBI-registered IAs, we are legally and ethically bound to act in the best interests of our clients. We do not sell or distribute any financial products. This ensures our guidance is 100% unbiased and conflict-free.
Deep fundamental research + robust valuation discipline.
Built on more than 15 years of equity research, our framework combines quality assessment, intrinsic value estimation, and a sensible margin-of-safety approach.
Process—not predictions.
We don’t rely on guesswork or market timing. Instead, we focus on asset allocation, risk management, and long-term compounding.
Technology + Human Intelligence.
We believe a combination of both is essential for investing success. We constantly innovate and upgrade in-house tools, financial X-rays, and portfolio analytics so that our team of analysts and advisors are equipped with the best.
Partner with Clients.
We follow a DIWM (Do-It-With-Me) approach where we partner clients in setting goals, financial planning, educating on our investing process and share decision-enabling resources transparently with our clients who retain control on execution.

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

Investing in stocks, mutual funds, debt, and gold
Quality-at-Reasonable-Price way of investing in stocks
Constructing Direct Stock Portfolios with Core, Booster, and Amplifier stocks
A Mutual Fund Portfolio that delivers consistent out-performance and meaningful diversification (low overlap)
Periodic review and rebalancing
Clear Buy-Sell-Hold, and Position-sizing frameworks